Table VI.
Association between ErbB4 expression and clinicopathological parameters in IDC.
| ErbB4 expression | ||||||
|---|---|---|---|---|---|---|
| Parameter | Negative (−) n, % | Weak-positive (1+) n, % | Medium-positive (2+) n, % | Strong-positive (3+) n, % | P-value | n |
| IDC | 58 | |||||
| Age, years | 0.610 | |||||
| ≤50 | 15 (38.5) | 13 (33.3) | 10 (25.6) | 1 (2.6) | 39 | |
| >51 | 8 (42.1) | 4 (21.1) | 7 (36.8) | 0 | 19 | |
| Lymph node metastases | 0.001 | |||||
| Negative | 13 (52) | 11 (44) | 1 (4) | 0 | 25 | |
| Positive | 10 (30.0) | 6 (18.2) | 16 (48.5) | 1 (3) | 33 | |
| IDC stage | 0.266 | |||||
| 0-I | 8 (53.3) | 4 (26.7) | 3 (20) | 0 | 15 | |
| II | 12 (40) | 8 (26.7) | 9 (30) | 1 (3.3) | 30 | |
| III–IV | 3 (23) | 5 (38.5) | 5 (38.5) | 0 | 13 | |
| IDC size | 0.628 | |||||
| ≤2 cm | 8 (44.4) | 6 (33.3) | 4 (22.2) | 0 | 18 | |
| >2 cm | 15 (37.5) | 11 (27.5) | 13 (32.5) | 1 (2.5) | 40 | |
| ER | 0.457 | |||||
| Negative | 5 (27.8) | 6 (33.3) | 7 (38.9) | 0 | 18 | |
| Positive | 18 (45) | 11 (27.5) | 10 (25) | 1 (2.5) | 40 | |
| PR | 0.118 | |||||
| Negative | 4 (21.1) | 8 (42.1) | 7 (36.8) | 0 | 19 | |
| Positive | 19 (48.7) | 9 (23.1) | 10 (25.6) | 1 (2.6) | 39 | |
P-value was obtained from non-parametric rank sum test. IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor.